Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Tacrolimus in Adults With Facial Non-segmental Vitiligo - VITAC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject male or female with age over 18 years old~2. Diagnosis of non-segmental (symmetrical) vitiligo~3. Presence of at least one vitiligo target-plaque on the face, with:~   Area greater than 3cm² Local Vitiligo Area Severity Index (VASI) score ≥ 50% Stable (no change in pigmentation or size over the last 3 months) Recent onset (less than 2 years duration)~4. Subject affiliated to the French social security system~Exclusion Criteria:~1. Progressive vitiligo over the last 3 months~2. Spontaneous ongoing repigmentation (documented in the last 3 months)~3. Previous topical Tacrolimus treatment in the last 3 months~4. Previous topical or systemic treatment in the last month:~   Topical or oral corticosteroid Topical vitamin D Phototherapy or laser Other topical treatment specific to vitiligo Other immunosuppressant or immunomodulator~5. Underlying dermatological disease (i.e.: history of atopic dermatitis, eczema, psoriasis), which, according to the investigator, could interfere with the study assessments~6. Known sensitivity to study drug or macrolides~7. Past history of skin cancer or lymphoma~8. Congenital or acquired immunodeficiency~9. Pregnant or breastfeeding women~10. Women without contraception~11. Absence of signed informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tacrolimus group (Type: EXPERIMENTAL): Target-lesion will be treated with the study treatment BID. The batch of treatment (Tacrolimus ointment 0.1% or placebo) will be randomized. All the patients will be treated during 6 months. Counselling on natural daylight exposition will also be given to all patients. During the 6-month observation period, relapse (worsening of VASI ≥ 25%) will be re-treated by the study treatment
- Control group (Type: PLACEBO_COMPARATOR): In the Control group, patients will receive the placebo ointment to be applied twice a day during 24 weeks.~Counselling on natural light exposure during the duration of the trial will be given.

Based on this trial design, predict the completion outcome and termination type (if applicable).